A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus

被引：0

作者：

Alexander, Roberta ^{[1
]}

Rey, Scott ^{[1
]}

Conklin, John ^{[1
]}

Domingues, Vinicius ^{[2
]}

Ahmed, Mansoor ^{[3
]}

Qureshi, Jazibeh ^{[4
]}

Weinstein, Arthur ^{[5
]}

机构：

[1] Exagen Inc, Vista, CA USA

[2] Florida State Univ, Daytona Beach, FL USA

[3] Arthrit Osteo Ctr KY, Richmond, KY USA

[4] Rheumatol Express, Catonsville, MD USA

[5] Loma Linda Univ, Voluntary Posit, Claremont, CA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0325

引用

页码：659 / 661

页数：3

共 50 条

[31] Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Furie, Richard
Buyon, Jill P.
Ramsey-Goldman, R.
Putterman, Chaim
Kalunian, Kenneth
O'Malley, Tyler
Conklin, John
Barken, Derren
Dervieux, Thierry
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S720 - S720
[32] Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Urbano, Marcela Munoz
Quintero-Gonzalez, Diana C.
Rojas, Mauricio
Rodelo, Joaquin
Alvarez, Alba Luz Leon
Gonzalez, Luis
Vasquez, Gloria
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4144 - 4146
[33] A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA and Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years
Ramsey-Goldman, Rosalind
Alexander, Roberta Vezza
Arriens, Cristina
Narain, Sonali
Massarotti, Elena
Wallace, Daniel J.
Saxena, Amit
Collins, Christopher
Putterman, Chaim
Kalunian, Kenneth
Sace, Armida
LaFon, Rowena
Ligayon, JoAnne
Conklin, John
Weinstein, Arthur
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[34] Cell-bound complement activation products are superior to serum complement C3 and C4 levels to detect complement activation in systemic lupus erythematosus: comment on the article by Aringer et al Reply
Aringer, Martin
Costenbader, Karen H.
Doerner, Thomas
Johnson, Sindhu R.
ARTHRITIS & RHEUMATOLOGY, 2020, 72 (05) : 860 - 861
[35] Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity
Hui-Yuen, J. S.
Gartshteyn, Y.
Ma, M.
O'Malley, T.
Conklin, J.
Eichenfield, A. H.
Imundo, L. F.
Dervieux, T.
Askanase, A. D.
LUPUS, 2018, 27 (14) : 2262 - 2268
[36] Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE
Rogers, Jennifer
Eudy, Amanda
Wojdyla, Daniel
O'Malley, Tyler
Pisetsky, David
Alexander, Roberta
Sun, Kai
Criscione-Schreiber, Lisa
Doss, Jayanth
Sadun, Rebecca
Maheswaranathan, Mithu
Clowse, Megan
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1095 - 1097
[37] CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS IN SLE: TREE RINGS OR BARNACLES?
Ahearn, J.
RHEUMATOLOGY, 2012, 51 : I1 - I1
[38] Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus
Li, J.
An, L.
Zhang, Z.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (01) : 48 - 53
[39] An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
Clarke, Ann E.
Goss, Tom
Piscitello, Andrew
Chandra, Tarun
O'Malley, Tyler
Dervieux, Thierry
Powell, Tami
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[40] Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus
O'Malley, Tyler
Xie, Fenglong
Su, Yujie
Clinton, Cassie
Zack, Debra J.
Haechung, Chung
Grabner, Michael
Curtis, Jeffrey R.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 1021 - 1032

← 1 2 3 4 5 →